Andrew N. Schiff - 04 Jun 2026 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Director
Issuer ticker: ACRS
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:15:16 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Rothman, Attorney-in-Fact

Key filing fact

Andrew N. Schiff filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 08 Jun 2026.

Key facts

This page summarizes Andrew N. Schiff's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 08 Jun 2026, 16:15.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001172252 Primary reporting owner

SCHIFF ANDREW N

Relationship: Director
Address: C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRS transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,580
Change %: +83%
Price
Shares after: 25,540
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

ACRS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 434,455
Date: 04 Jun 2026
Ownership: By Aisling Capital IV LP
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +42,350
Change %
Price: $0.000000^*
Shares after: 42,350
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,350
Exercise price: $4.71
Footnotes: F3, F4

ACRS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +10,987
Change %
Price: $0.000000^*
Shares after: 10,987
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,987
Exercise price
Footnotes: F1, F4, F5

ACRS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -11,580
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,580
Exercise price
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Footnote F2

The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Footnote F3

The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

Footnote F4

This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

Footnote F5

The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

Footnote F6

The shares underlying these restricted stock units vested on June 5, 2026.